Physicians

Departments / Divisions

• Medicine / Medicine - Oncology
• Surgery / Surgery-Neuro Oncology

Address
DUMC 3624
Durham, NC 27710

Appointment Telephone
919-684-5301 (New patients), 919-668-6688 (Return patients)

Office Telephone
919-681-4047

Fax Telephone
919-684-6674

Training

• MD, University of Vermont College of Medicine, 1983

Residency

• Internal Medicine, St. Francis Medical Center (Connecticut), 1983-1986

Fellowship

• Hematology/Oncology, Dartmouth-Hitchcock Medical Center (New Hampshire), 1986-1989

Clinical Interests
Primary brain tumors, neuro-oncology, CNS metastases

Research Interests


Dr. James J. Vredenburgh is devoted to improving the treatment of breast cancer.  The majority of his work focuses on studies of the use of high dose chemotherapy with hematopoietic support for breast cancer.  In addition to the efficacy of high dose chemotherapy, Dr. Vredenburgh studies improvements in supportive care following high dose chemotherapy, enhancing the engraftment following high dose chemotherapy and tumor cell contamination of the bone marrow or peripheral blood and its impact on treatment results.

Dr. Vredenburgh's laboratory research focuses on the detection of small numbers of malignant cells in the bone marrow or peripheral blood.  He has developed a sensitive and specific two color immunofluorescent technique using four monoclonal antibodies to detect breast cancer cells mixed with normal hematopoietic cells.  Dr. Vredenburgh is continuing to study improvements in the detection of small numbers of malignant cells, enhancements of the two color immunofluorescent technique, PCR detection of malignant cells and growing the malignant cells in culture.  The laboratory research has translated into important clinical findings.  It is has become clear that contamination of the bone marrow with malignant cells has a negative impact on disease-free and overall survival in some patients.  In addition to the tumor cell detection work, Dr. Vredenburgh has developed a variety of purging techniques in the laboratory. The work has primarily focused on negative purging, using anti-breast cancer monoclonal antibodies and immunomagnetic beads.  The laboratory work has lead to a large clinical trial. More recently Dr. Vredenburgh has studied purging using a variety of CD34 selection techniques.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Genentech, Inc (Roche Holding)
• Merck & Co. USA (not assoc'd with Merck KGaA)
• Roche

Representative Publications
Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonoas P, Anderson S, Everett T, Harpole D, Moore M, Berry D, Vredenburgh J, Rizzieri D, Bentley R. Comparison of Methods and Outcome of HER2 Positivity after High-Dose Chemotherapy in Metastatic Breast Cancer Patients. Accepted for publication J Clin Oncol. Nov. 2000. (2000)

Abruzzese E, Radford JE, Miller JS, Vredenburg JJ, Rao PN, Pettenati MJ, Cruz JM, Perry JJ, Amadori S, Hurd DD. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 94(5):1814-1819, 1999. (1999)

Nieto Y, Cangnoni PJ, Shpall EJ, Xu X, Murphy J, Vredenburgh J, Chao NJ, Bearman SI, Jones RB: A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clinical Cancer Research 5:3425-3431, November, 1999. (1999)

Petros WP, Broadwater G, Berry D, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP, Colvin OM, Peters WP. Association of high dose cyclophosphamide, cisplatin and carmustine pharmacokinetics with response, toxicity and dosing weight in patients with primary breast cancer. Accepted for publication Clinical Cancer Research, 1999. (1999)

Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburg JJ, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-rish population. Blood 92(3):737-744, 1998. (1998)